Psyence Biomedical ltd (PBM) - News Archive

Psyence Biomedical Strengthens Its Scientific Advisory Board with Renowned Psychopharmacologist Dr. Dan J. Stein Amidst Ongoing ChallengesIn a strategic move aimed at enhancing its research capabilities, Psyence Group I...

Psyence Biomedical Ltd. has recently made significant strides in advancing its active Phase IIb clinical trial, focusing on the exploration of potential therapeutic applications. The company has announced that patient s...

In a remarkable turn of events, a recent independent valuation has appraised PsyLabs, a subsidiary of Psyence Biomedical Ltd, at approximately $2 million. This valuation represents a significant doubling of its stake va...

In a significant development for Psyence Biomedical Ltd. (Nasdaq: PBM), the company has cleared a substantial hurdle regarding its listing on the Nasdaq exchange. On November 20, 2024, Psyence announced that it received...

Psyence Biomedical Ltd. Announces Effective Date for 1-for-75 Share Consolidation Amidst Recent Challenges and Strategic MovesIn a critical announcement on November 19, 2024, Psyence Biomedical Ltd. (Nasdaq: PBM), a com...

Psyence Group Completes Stake Disposal as Strategic Shift Amidst Nasdaq Challenges and New Growth OpportunitiesIn a significant move for the Psyence Group, the company has successfully closed the disposal of its stake i...

PsyLabs: The Vanguard of Nature-Derived Psychedelic Therapies Amidst Market ShiftsIntroductionIn an ever-evolving landscape of mental health treatments, PsyLabs stands at the intersection of pharmaceutical-grade product...

PsyLabs Partners with Psyence Biomed to Advance Psilocybin Development for Alcohol Use Disorder Amidst Evolving Industry LandscapeIn a pivotal development for the rapidly advancing field of psychedelic medicine, PsyLabs...

In a significant development that underscores the dynamic nature of the emerging psychedelic sector, Psyence Group Inc. (Psyence Group or the Company) has recently announced a debt-for-equity swap agreement with its NAS...

By October 4, 2024 In a move that startled investors and industry experts alike, Psyence Biomedical Ltd. (Nasdaq: PBM), a pioneering player in the development of psilocybin-based therapeutics, announced today it will no...

In a notable strategic move within the rapidly evolving psychedelic landscape, Psyence Group has announced its decision to enter into an agreement to dispose of its stake in PsyLabs, a pioneering entity renowned for dev...

Psyence Biomedical Aims to Transform Palliative Care Through Groundbreaking Psilocybin ResearchAs the discourse surrounding mental health treatment intensifies, so too does the need for innovative solutions. In recent y...

Psyence Biomedical Ltd (NASDAQ: PBM), a key player in the emerging landscape of psychedelic medicine, recently issued a comprehensive update aimed at its shareholders. The update not only highlighted the company’s recen...

Unlocking Potential: Psyence Biomedical s Phase IIb Study on Nature-Derived Psilocybin as a Treatment for Adjustment Disorder in Palliative Care In the evolving landscape of mental health treatment, the importance of in...

A Troubling Turn: Psyence Biomedical Faces Nasdaq Delisting as Share Price PlummetsOn September 12, 2024, Psyence Biomedical Ltd. (Nasdaq: PBM) was faced with a significant setback when the company received a staff dete...

Mark J. Andrews, Ph.D. Department of Pharmacology, CSIMarket.com : Psyence Biomed Ltd, a pioneering entity in the domain of psychedelic biotechnology, has announced the initiation of its first trial site in Australia fo...

: This article discusses Psyence Biomed’s recent licensing agreement with PsyLabs to supply nature-derived psilocybin for clinical evaluation in the treatment of Alcohol Use Disorder (AUD) and other Substance Use Disord...

Psyence Biomed Secures $25 Million Equity Line of Credit with White Lion Capital: A Strategic Move for Financial Stability and Growth Psyence Biomedical Ltd. a notable entity in the biotech sector, has announced a signi...

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLCPsyence Biomedical Ltd. (Nasdaq: PBM) has recently made a significant announcement regarding its entry into a $25 millio...

Psyence Group s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialNEW YORK, July 26, 2024 - Psyence Group Inc (Psyence...